Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICU
stocks logo

ICU

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
245.00K
+265.67%
-0.110
-87.78%
375.00K
+27.99%
-0.110
-75%
473.00K
+39.94%
-0.110
-38.89%
Estimates Revision
The market is revising Downward the revenue expectations for SeaStar Medical Holding Corporation (ICU) for FY2025, with the revenue forecasts being adjusted by -13.98% over the past three months. During the same period, the stock price has changed by -54.83%.
Revenue Estimates for FY2025
Revise Downward
down Image
-13.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-12.5%
In Past 3 Month
Stock Price
Go Down
down Image
-54.83%
In Past 3 Month
Wall Street analysts forecast ICU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ICU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.359
sliders
Low
1.00
Averages
1.00
High
1.00
Current: 0.359
sliders
Low
1.00
Averages
1.00
High
1.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for SeaStar Medical Holding Corp (ICU.O) is -0.82, compared to its 5-year average forward P/E of -0.89. For a more detailed relative valuation and DCF analysis to assess SeaStar Medical Holding Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.89
Current PE
-0.82
Overvalued PE
0.06
Undervalued PE
-1.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
25.87
Current PS
0.00
Overvalued PS
75.12
Undervalued PS
-23.38
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 109.01% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 109.01% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ICU News & Events

Events Timeline

(ET)
2025-12-02
08:30:00
SeaStar Medical Reduces SAVE Registry Enrollment from 300 to 50 Patients
select
2025-11-17 (ET)
2025-11-17
08:46:48
Michael Messinger Named CFO of SeaStar Medical
select
2025-09-29 (ET)
2025-09-29
08:59:39
SeaStar Medical Reveals Initial Findings from SAVE Surveillance Registry
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
SeaStar Medical Reduces FDA Surveillance Requirement to 50 Patients
  • Reduced Monitoring Requirement: The FDA has decreased the mandatory enrollment size for the SAVE Surveillance Registry from 300 to 50 patients, indicating confidence that device safety can be demonstrated with fewer patients, thereby accelerating the market adoption of QUELIMMUNE therapy.
  • Significant Survival Rate Improvement: Among the first 21 patients in the SAVE Surveillance Registry, QUELIMMUNE therapy reported zero device-related adverse events and a 70% survival rate at 90 days, providing new hope for pediatric patients suffering from acute kidney injury.
  • Expanded Market Opportunity: SeaStar Medical anticipates that by reducing the required patient enrollment, it can facilitate smoother adoption of QUELIMMUNE therapy, potentially capturing a share of the estimated $100 million pediatric acute kidney injury market in the U.S., thus enhancing revenue potential.
  • Clinical Data Validation: Preliminary results from the SAVE Surveillance Registry indicate survival rates of 76% at Day 28 and 71% at Day 60 for QUELIMMUNE therapy, demonstrating a 50% reduction in mortality compared to historical data, further validating the therapy's efficacy.
[object Object]
Preview
2.0
11-26NASDAQ.COM
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO

  • Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.

  • SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.

  • Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.

  • Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.

[object Object]
Preview
1.0
11-24NASDAQ.COM
SeaStar Medical Scheduled to Present at NobleCon21 Investor Conference on December 3, 2025

  • Company Presentation: SeaStar Medical Holding Corporation will present at the NobleCon21 Investor Conference on December 3, 2025, discussing its therapeutic platform, commercial progress, and financial positioning.

  • Product Overview: The company's first commercial product, QUELIMMUNE (SCD-PED) therapy, is FDA-approved for life-threatening acute kidney injury in critically ill pediatric patients, showing promising survival rates in treated patients.

  • Clinical Trials: SeaStar is conducting a pivotal phase 3 trial, NEUTRALIZE-AKI, for adults with acute kidney injury, and a feasibility study, NEUTRALIZE-CRS, for acute heart failure patients, with positive interim results reported.

  • Financial Performance: For Q3 2025, SeaStar reported a net revenue increase from QUELIMMUNE sales, a narrowed net loss, and a cash position of $13.8 million, supported by recent equity offerings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is SeaStar Medical Holding Corp (ICU) stock price today?

The current price of ICU is 0.359 USD — it has increased 5.59 % in the last trading day.

arrow icon

What is SeaStar Medical Holding Corp (ICU)'s business?

SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).

arrow icon

What is the price predicton of ICU Stock?

Wall Street analysts forecast ICU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is SeaStar Medical Holding Corp (ICU)'s revenue for the last quarter?

SeaStar Medical Holding Corp revenue for the last quarter amounts to 183.00K USD, increased 169.12 % YoY.

arrow icon

What is SeaStar Medical Holding Corp (ICU)'s earnings per share (EPS) for the last quarter?

SeaStar Medical Holding Corp. EPS for the last quarter amounts to -0.13 USD, decreased -88.18 % YoY.

arrow icon

What changes have occurred in the market's expectations for SeaStar Medical Holding Corp (ICU)'s fundamentals?

The market is revising Downward the revenue expectations for SeaStar Medical Holding Corporation (ICU) for FY2025, with the revenue forecasts being adjusted by -13.98% over the past three months. During the same period, the stock price has changed by -54.83%.
arrow icon

How many employees does SeaStar Medical Holding Corp (ICU). have?

SeaStar Medical Holding Corp (ICU) has 19 emplpoyees as of December 05 2025.

arrow icon

What is SeaStar Medical Holding Corp (ICU) market cap?

Today ICU has the market capitalization of 12.80M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free